Skip to main content
. 2022 Jul 27;32:100823. doi: 10.1016/j.neo.2022.100823

Figure 4.

Figure 4

In vivo efficacy of SOMCL-19-133 by subcutaneous injection and the plasma drug concentrations-time profiles in SD rats. (a and b) The inhibitory effects of SOMCL-19-133 on (a) human colon cancer HCT-116 and (b) human leukemia MV-4-11 xenograft models. Mice bearing subcutaneous xenografts were given with the indicated dose of SOMCL-19-133 by s.c. injection once daily, or MLN4924 (60 mg/kg, BID, 5on/5off) for 21 days (n = 6). The tail indicated the tumor disappeared in that mouse. (c) The antitumor effects of SOMCL-19-133 on human non-small cell lung cancer NCI-H1975 in vivo model. Mice bearing with tumors were dosed with SOMCL-19-133 (3 mg/kg; s.c.) daily for 14 days (n = 6) and were sacrificed on day 24 (vehicle group) or day 45 (SOMCL-19-133-treated group) after withdrawal of the drug. (d) Plasma concentration-time profile of SOMCL-19-133 and MLN4924 at 3 mg/kg p.o. in SD rats, n=3. (e) Plasma concentration-time profile of SOMCL-19-133 and MLN4924 at 1 mg/kg i.v. in SD rats, n=3. Data were represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.